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Summal'y 
We have previously shown that prostaglandin  E2 and other cAMP elevating agents inhibit the 
nuclear transcription of the human IL-2 gene by interfering with a Ca2+-sensitive T cell signal 
transduction pathway. Calcineurin,  a Ca  2  +/calmodulin-dependent  2B protein phosphatase, is an 
essential component of the T  cell receptor signal transduction pathway leading to IL-2 gene 
expression.  We have therefore tested the hypothesis  that this phosphatase  may be a target for 
the inhibitory effects of cAMP on IL-2 gene transcription.  We report here that PGE2 markedly 
reduces the IL-2 promoter activity that is induced by a constitutively active form of calcineurin. 
In contrast to the complete inhibition of promoter activity produced by the immunosuppressants 
cyclosporin A and FK-506, this partial block suggests that PGE2 modulates downstream events 
needed for lymphokine gene activation.  Overexpression of calcineurin in Jurkat cells decreases 
their apparent  sensitivity  to the inhibitory effects of PGEz consistent  with the fact that this 
enzyme plays a physiological role in dephosphorylating substrates of cAMP-dependent kinases 
in several tissues. These results provide evidence that cAMP-dependent pathways may antagonize 
calcineurin-regulated  cascades for T  cell activation  in vivo, and suggest  crosstalk between the 
Ca  2+  and the cAMP signaling  pathways during T  cell activation. 
p rostaglandins  (PG) of the E series have been shown to 
modulate immune responses by inhibiting T cell activa- 
tion events including IL-2 gene expression (1-4).  PGE2 re- 
lease from macrophages  is induced by diverse stimuli such 
as phagocytosis, immune complexes, and complement prod- 
ucts (5, 6). The effects of PGE2 are mediated by the intra- 
cellular second messenger, cAMP, through binding to its in- 
tracellular receptor protein kinase A (PICA). As with other 
agents that increase cAMP (histamine, adenosine, forskolin, 
and cholera toxin),  the mechanism by which PGE2 activates 
PICA involves the binding of CAMP to the inactive tetrameric 
holoenzyme dissociating it into two regulatory and two cata- 
lytic subunits  (7). This kinase-mediated  activation leads to 
inhibition of IL-2R expression, IL-2 production (mediated 
by both a decrease in IL-2 nuclear transcription and IL-2 
mRNA stability)  (8), and T  cell proliferation  (1-4). 
IL-2 gene transcription is controlled by a promoter region 
extending ~326 bp upstream of the transcription start site. 
Both an increase of cytoplasmic-free calcium and activation 
of protein kinase C (PKC) are required for its transcription 
in resting T cells (9, 10). Recent findings have identified cal- 
cineurin, a Ca2+/calmodulin-dependent (type 2B) serine/ 
threonine protein phosphatase,  as a key enzyme needed for 
IL-2 promoter activity (11, 12). A deletion mutant (ACaM- 
AI) of the calcineurin catalytic subunit (11) has been shown 
to mimic proteolyzed forms of the phosphatase  known to 
have Ca2+-independent,  constitutive phosphatase activity in 
vitro (13, 14); this has allowed demonstration of IL-2 pro- 
motet activation in the presence ofphorbol ester alone (11). 
We have previously  shown that cAMP elevating agents 
blocked IL-2 gene transcription by inhibiting Ca  2  +-depen- 
dent pathways of T cell activation. In vitro data have shown 
that calcineurin exhibits a relatively  narrow substrate specifidty, 
preferring substrates of cAMP-dependent kinases (including 
the regulatory subunit of the kinase itself) (15-18). More im- 
portantly, it appears that this phosphatase plays a physiolog- 
ical role in counteracting cAMP-dependent signal pathways 
in skeletal muscle (19) and in intact  kidney cells (20). We 
therefore hypothesized that a different type of reciprocal rela- 
tionship may exist in T cells, i.e., that cAMP-mediated inhi- 
bition of IL-2 gene transcription  may downregulate calci- 
neurin-dependent pathways of lymphokine gene activation. 
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with plasmids carrying the mutant calcineurin (ACaM-AI) 
and the IL-2 promoter in Jurkat  cells. 
Materials and Methods 
Cell Culture.  Human Jurkat T cells were cultured in RPMI- 
1640 supplemented with 10% heat-inactivated  FCS, 25 #g/ml gen- 
tamicin, and 5  x  10-s M 2-ME (Sigma Chemical Co., St. Louis, 
MO). Cultures were stimulated at the indicated time points and 
concentrations with the following reagents: cholera toxin (CT; List 
Biol. Laboratories, Inc.,  Campbell,  CA),  ionomycin, forskolin, 
8-bromo-cAMP (8 Br-c.AMP),  or 3-isobutyl-l-methyl-xanthine, (all 
from Sigma Chemical Co.).  cAMP devating agents were added 
into ceil cultures 30 rain before stimulation. 
Plasmids.  Plasmid  ACaM-AI is a deletion mutant of the cata- 
lytic subunit  of the wild type murine calcineurin, the sequence 
of  which has 99% homology to the corresponding human subunit 
(11). As discussed dsewhere  (11), ACaM-AI was constructed by 
polymerase chain reaction (PCR) amplification of a CN~x-4 tem- 
plate and insertion of a fragment encoding amino acids 1 to 398 
into the Sinai site of pUC18. Consequently the 5' and 3' untrans- 
lated sequences present in CNc~4 were also deleted. The done was 
subsequently  inserted into the EcolLI  site of  pcDbSRc~296. ACaM- 
AI lacks functional CaM-binding and autoinhibitory domains. This 
truncation was designed to mimic proteolyzed forms of the phos- 
phatase known to have CaZ§  constitutive phospha- 
tase activity in vitro (13, 14). In control experiments, the expres- 
sion vector alone without calcineurin  was used. The reporter phsmid 
IL-2 CAT contains the human I1.,2 promoter (base pairs -448 to 
+43) directing  the transcription  of the chloramphenicol acetyl- 
transferase (CAT) gene. This plasmid also includes an SV40 poly- 
adenylation site between vector sequences and  -448 of the IL-2 
promoter to  prevent  vector-dependent  transcription  from con- 
tributing to the observed CAT activity. Plasmid SV40 CAT vector 
(Promega Corp., Madison, WI) contains the SV40 enhancer and 
promoter regions linked to the CAT gene. 
DNA  Transfections.  Transfections of lymphoid cells were car- 
fled out by the (DEAE)-dextran method as previously described 
(21). To decrease  variations  in transfection  efficiency,  ceils  were trans- 
fected in single batches, which were then separated into different 
drug treatment groups. For each treatment,  1.5-2  x  107 ceils har- 
vested in log phase of growth (3-5  x  10  s ceils/ml) were incubated 
with 20 #g DNA and 100 #g/ml DEAE-dextran  in serum-free 
KPMI-1640 for 70 min at room temperature.  After two washes 
with  serum-free  RPMI-1640,  they  were  replated  in  complete 
medium.  24 h after transfection, ceils were treated with various 
concentrations of cAMP elevating agents for 30 rain.  Then they 
were stimulated for 12 h with ionomycin 0.7 #g/ml and 20 ng/ml 
of phorbol myristate acetate (PMA). In titration experiments this 
dose of ionomycin was found to induce maximal reporter gene ac- 
tivity. After stimulation,  cells were harvested and extracts were 
prepared by rapid freeze-thawing. Protein concentration  was de- 
termined by the Bradford assay and equivalent amounts of protein 
extracts were assayed for enzyme activity. 
Chloramphenicol  A rainotransferase  (CAT) Assay.  The CAT assay 
was carried out as described previously (21) by the incubation of 
50 #g of call lysate with 0.1 #Ci of [14C]chloramphenicol (sp act 
57.3 mg/mmol, NEN Research Products, Boston, MA) in the pres- 
ence of 9 mM acetyl-coenzyme A (Pharmacia Inc., Piscataway, NJ) 
for 3 h at 37~  Acetylated and unacetylated cMoramphenicol  were 
separated by thin layer chromatography. Conversion of [l~C]chlor- 
amphenicol to its acetylated forms was quantified by the use of 
a Betagen Betascope (Waltham, MA). 
Results 
cAMP Inhibits Protein Kinase C- and Calcium-mediated trans- 
Activation of  the IL-2 Promoter.  In earlier studies, we showed 
that cAMP partially inhibits ('~50% inhibition) the nuclear 
transcription of the human IL-2 gene as determined by nu- 
clear run-offassays (8). To determine whether this inhibition 
is mediated through interference with the transcriptional ac- 
tivity of the IL-2 promoter,  Jurkat cells were transiently trans- 
fected with plasmid IL-2 CAT which contains the IL-2 pro- 
moter region driving the expression of CAT gene (see Materials 
and Methods).  Cells were stimulated with ionomycin and 
PMA in the presence or absence of PGE2, 8 Br-cAMP, for- 
skolin, or CT. All four cAMP elevating agents reduced the 
CAT activity of the IL-2 promoter plasmid. Fig. 1 A  shows 
the results using PGE2 as the cAMP elevating agent. In four 
different experiments PGE2 inhibited the activity of the IL-2 
promoter in a dose-dependent fashion. Inhibition of IL-2 pro- 
moter activity by PGE2 was partial even at suprapharmaco- 
logic doses (60% inhibition with 10 -4 M PGE2). Partial in- 
hibition of IL-2 promoter activity was not due to degradation 
of cAMP by cAMP phosphodiesterase because addition of 
its inhibitor isobutyhnethyLxanthine  (0.5-5 raM) did not affect 
the level of inhibition (not shown). Similar results were ob- 
Figure  1.  PGE2  specifically  inhibits the Ca  2  +- and PKC-mediated  trans- 
activation of the I1_-2 promoter.  Jurkat cells were transiently transfected 
with the plasmid Ib2 CAT which contains the Ib2 promoter  driving the 
expression of CAT gene (A), or the control plasmid SV40 CAT which 
contains the SV40  enhancer  and promoter  regions  linked  to the CAT gene 
(B), 24 h after transfection,  cells  were incubated  for ,'-30 rain with PGE2 
(10-6-10 -9 M) and then stimulated with ionomycin  and PMA. Cell ex- 
tracts were prepared 12 h later and assayed  for CAT activity. Acetylated 
and unacetylated  chloramphenicol  were separated by thin layer  chroma- 
tography. Conversion  of [14C]chloramphenicol  to its acetylated  forras  was 
quantified using a Betagen Betascope.  Results (expressed  as percentage  of 
maximum activity)  represent  the mean (+ 2 SD) of four independent  ex- 
periments. 
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fically, the doses needed to obtain 50%  inhibition were as 
follows: PGE2, 10 -6 M; 8BrcAMP, 10 -3 M; forskolin, 10 -4 
M; and CT, 1 ng/ml. The inhibitory effect of CAMP on IL-2 
promoter activity was specific since the activity of an un- 
related promoter (SV40 CAR., control vector) was not affected 
(Fig.  1 B). 
ACaM-AI trans-Activates the 11..-2 Promoter in Slmerg  7 with 
PMA.  To investigate the role of calcineurin in the activa- 
tion of the IL-2 promoter, we cotransfected a plasmid con- 
taining the IL-2 promoter linked to a CAT gene along with 
plasmid ACaM-AI into Jurkat cells. Cotransfection of ACaM- 
AI, in the presence or absence of 0.7 #g/m1 ionomycin, did 
not affect the IL-2 promoter activity (not shown). Stimula- 
tion with PMA alone did not increase IL-2 promoter activity 
in vector-treated cells, but did so only in the presence  of 
ACaM-AI (Fig.  2 A). 
The combination of ionomycin and PMA was tested next. 
In the absence of ACaM-AI, IL-2 promoter activity was twice 
that of cells stimulated with PMA alone in the presence of 
ACaM-AI (Fig. 2 B). Overexpression of calcineurin by means 
of ACaM-AI further induced IL-2 promoter activity (by 1.7- 
to 2.3-fold) suggesting that in addition to calcineurin, other 
Ca  2  +-dependent pathways are also involved in IL-2 promoter 
activity (Fig. 2 B). These results confirm that ACaM-AI can 
partially substitute for the Ca2+-requirements of IL-2 pro- 
moter activation as reported previously (11, 12), and that its 
overexpression  further induces IL-2 promoter activity. 
cAMP Inhibits the Calcineurin-deFendent trans-Activation of  the 
11..-2  Promot~  Having demonstrated that calcineurin can par- 
tially substitute for the CaZ§  pathways of T  cell 
activation, we next examined whether cAMP antagonizes its 
action on IL-2 promoter activity. As shown in Fig. 3, PGE2 
inhibited the IL-2 promoter activity induced by the syner- 
gistic actions of ACaM-AI and phorbol ester. Similar dose- 
dependent inhibition was also observed when other cAMP 
elevating agents were used (not shown). We have previously 
shown that PKC-dependent pathways of T cell activation are 
not inhibited by cAMP (8). Thus, inhibition of IL-2  pro- 
moter activity by cAMP in this experiment, can be attrib- 
uted to cAMP-mediated events inhibiting the activity of ei- 
ther  the  calcineurin per  se,  or  more distant  sites  of the 
calcineurin-dependent pathway of T  cell activation. It is of 
interest that inhibition of IL-2 promoter activity in this ex- 
periment  (where  ACaM-AI  substitutes  for  the  Ca  2+- 
dependent  pathway for its activation) is partial and comparable 
Figure 2.  The mutant calcineurin plasmid ACaM-AI acts in synergy 
with phorbol esters to mediate the trans-activation  of the Ib2 promoter. 
Jurkat  cells were transiently transfected with 5 t~g of plasmid IL-2 CAT 
alone or with the plasmid ACaM-AI (15/~g). Cells were stimulated with 
P/VIA alone (,4), or in combination  with ionomycin  (B). Cell lysates were 
examined for CAT activity and analyzed as described in Fig. 1, Results 
(expressed as percentage of activity observed when cells were stimulated 
with ionomycin  and PMA in the absence of ACaM-AI) are representative 
of three  independent experiments  (mean  •  2 SD). 
Figure 3.  PGE2 inhibits  the  ACaM-AI  and  PMA  induced  trans- 
activation of Ib2 promoter. Jurkat cells were cotransfected with plasmids 
IL-2 CAT (5/~g) and ACaM-AI (15 #g) and stimulated with PMA alone 
in the presence or absence of PGE2 (10-~-10 -9 M). Cell lysates were ex- 
amined for CAT activity as described in Fig. 1. Results (expressed as per- 
centage of maximum activity) are representative of three independent ex- 
periments  (mean  _+  2 SD). 
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Figure  4.  ACaM-AI decreases the sensitivity of 1I.-2 promoter to 
PGE2. Jurkat cells were cotransfected  with plasmid IL-2 CAT (5 #g) in 
combination  with ACaM-AI  (15 ktg) (+ ACaM-AI  or its vector -  ACaM- 
AI) and stimulated  with ionomycin  and PMA in the presence  of PGE2 
(10-4-10 -9 M). Lysates  were analyzed  for CAT activity as described  in 
Fig. 1. CAT activity  is plotted as percent activity  in lysates of transfected 
cells that were not treated  with PGE2. Results represent  five independent 
experiments (mean _+ SD). Arrows  indicate  the doses of PGE2 required 
to obtain 50% of the maximum inhibitory effect. 
to the inhibition observed in Fig. 1, whereas IL-2 promoter 
activity was under the influence of all Ca  2  +-dependent path- 
ways (see Discussion). 
Overexpression of  A CaM-AI Renders Cells More Resistant to 
the Inhibitory Effects of PGE2.  Transfection of Jurkat cells 
with calcineurin expression plasmids increases the calcineurin 
concentrations and superinduces the IL-2 promoter activity 
(Fig. 2). Thus, in the presence of excess calcinenrin, one might 
expect we would predict that the ICs0 for cAMP-dependent 
inhibition would increase. Calls were cotransfected with the 
IL-2 promoter and either plasmid ACaM-AI, or its expres- 
sion vector alone, and stimulated with ionomycin and PMA. 
However, in  the presence of ACaM-AI  the ICs0  (defined 
here as the concentration required to obtain 50% of the max- 
imum inhibitory effect) for PGE2  increased by '~3.4-fold 
(5.8 nM vs. 20 nM) (Fig.  4).  In this experiment, the dose 
of PGE2 required to obtain a substantial inhibitory effect on 
IL-2 promoter activity  ('~10 -s  M),  is comparable to  the 
dose of PGE2 that is necessary to elevate cAMP in Jurkat 
cells (22) suggesting that its effect is physiologically relevant 
and mediated through cAMP. These results provided further 
evidence to support the notion that cAMP inhibits calcineurin- 
dependent pathways of T  cell activation. 
Discussion 
In this study we have demonstrated that agents that in- 
crease intracellular cAMP in Jurkat T  cells (22) also inhibit 
IL-2 promoter activity by counteracting calcineurin-dependent 
pathways of T  cell activation.  In fact, one of these agents 
(PGE2) did so at effector concentrations that are likely to 
occur physiologically, suggesting a central role for cAMP in 
mediating these effects. 
The partial  inhibition  of the Ca  2+  and/or  calcineurin- 
dependent activation of IL-2 promoter activity is intriguing. 
Data presented here and elsewhere (11) have suggested that 
in addition to calcinenrin, other Ca2*-dependent pathways 
that do not utilize calcineurin participate in IL-2 gene tran- 
scription. However, partial inhibition of IL-2 promoter ac- 
tivity was also observed in experiments where calcineurin alone 
substituted for the Ca  2+ signal.  Calcineurin is essential for 
IL-2 promoter activity and its inhibition by cydosporin A 
effectively blocks IL-2 gene transcription (11, 12, 21). The 
partial inhibition of IL-2 promoter activity by cAMP elevating 
agents observed in these experiments suggests that their effect 
may be exerted at more distal sites in the calcineurin-regulated 
pathway. Alternatively, calcinenrin may activate several dis- 
crete trans-activating pathways (23) and the partial inhibition 
by PGE2 may reflect selective blockades of some, but not all, 
of these signaling events. 
The  small,  but  reproducible,  shift  in  PGE2  sensitivity 
caused by overexpression of calcineurin may indicate a role 
of cAMP-dependent kinase substrates in modulating gene tran- 
scription. Calcineurin has been shown to dephosphorylate 
inhibitor-1 (I-1) and a related gene product, the dopamine 
and cAMP regulated phosphoprotein (DARPP) (15, 16). Both 
of these proteins, once phosphorylated by PKA, inhibit pro- 
tein phosphatase-1 (PP-1),  a relatively broad-specificity en- 
zyme (18); the dephosphorylation of I-1 and DARPP-32 by 
calcineurin activates PP-1, thus promoting the dephosphor- 
ylation of substrates for PICA. Similarly, dephosphorylation 
of the RII subunit of PKA by calcineurin facilitates its reas- 
sociation with the catalytic subunit to reform the inactive 
holoenzyme, further antagonizing the action of cAMP. These 
mechanisms operating either alone or in combination may 
allow signals that  act via Ca  2+  to  attenuate the action of 
cAMP (18, 24). It is conceivable that analogous mechanisms 
may be involved in downregulating IL-2 promoter activity. 
In addition to PGE2 released by activated macrophages at 
sites of inflammation, stimulation of T cells through the CD2 
(25) or CD3 (26) cell surface molecules also increases cAMP 
level, cAMP may represent an important mechanism to rap- 
idly attenuate the transcription of IL-2 once the inducing 
stimulus is removed (25). Consistent with these immunosup- 
pressive effects of PGE2 in vitro are the findings that mis- 
oprostol,  a PGE1 analogue, reduces the incidence of acute 
rejection in renal transplant recipients (27). These studies pro- 
vide  evidence  for  crosstalk  between  the  Ca  2§  and  the 
cAMP-pathways in human T cells and identify the calcinenrin 
pathway as an essential component of this interaction, cAMP 
elevating agents may provide a useful tool to further dissect 
the  molecular  events  associated  with  T  cell  activation. 
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